Antibodies from patients infected with SARS-CoV in 2003 cross-neutralised SARS-CoV-2 in vitro: Study

-

Antibodies from patients infected with SARS-CoV in 2003 cross-neutralised SARS-CoV-2 in vitro: Study

Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralised SARS-CoV-2 infection in cultured cells, according to a new study. The study was published in the journal --Science Advances

Comments

Post a Comment

Popular posts from this blog

India’s health budget fourth lowest in world, accoring to Oxfam

-
  India’s health budget fourth lowest in world, accoring to Oxfam Afghanistan and India set aside the same share for health in their budgets, 4%, just above a quarter of the recommended spending and one-third of what the second poorest country in the world, Burundi, did. And that may have affected how far people were shielded from the Covid-19 outbreak, the latest ‘Commitment to Reducing Inequality Index 2020’ by international charity Oxfam says.
Read more

BANK Q & A -9

-
Image
  81. Which of the following contracts involves future exchange of assets at a specified price? [A] future contract [B] forward contract [C] Present contract [D] Spot contract Hide Answer Correct Answer:  B [forward contract] Notes: A forward contract is a private agreement between two parties giving the buyer an obligation to purchase an asset (and the seller an obligation to sell an asset) at a set price at a future point in time. 82. Which of the following is best described as selling a synthetic asset and simultaneously buying the actual asset? [A] Arbitrage [B] Diversifying [C] Speculating [D] Hedging Hide Answer Correct Answer:  A [Arbitrage] Notes: Arbitrage is the simultaneous purchase and sale of an asset to profit from an imbalance in the price. It is a trade that profits by exploiting the price differences of identical or similar financial instruments on different markets or in different forms. 83. Which of the following indicates the wealth of a person? [A] Ba...
Read more

Vaccine storage issues could leave 3 billion people without access

-
Image
The chain breaks here, in a tiny medical clinic in Burkina Faso that went nearly a year without a working refrigerator. From factory to syringe, the world's most promising coronavirus vaccine candidates need non-stop sterile refrigeration to stay potent and safe. But despite enormous strides in equipping developing countries to maintain the vaccine ``cold chain,'' nearly 3 billion of the world's 7.8 billion people live where temperature-controlled storage is insufficient  or an immunization campaign to bring COVID-19 under control. The result: Poor people around the world who were among the hardest hit by the virus pandemic are also likely to be the last to recover from it. The vaccine cold chain hurdle is just the latest disparity of the pandemic weighted against the poor, who more often live and work in crowded conditions that allow the virus to spread, have little access to medical oxygen that is vital to COVID-19 treatment, and whose h ealth systems lack labs, suppl...
Read more